Riverdale, GA

Infinite Clinical Trials

Gastroparesis

Colitis

Colorectal Cancer

Ulcer

Ulcerative Colitis

Hot Flashes

Human Influenza

Cardiovascular Diseases

Relamorelin

Upadacitinib

ABT-494

fezolinetant

Methotrexate

Allergan

AbbVie

Astellas

Exact Sciences Corporation

Guardant Health

Mass General Brigham

Yiling Pharmaceutical

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Infinite Clinical Trials | Riverdale, GA

Site insights

Work at this site?

Active trials

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

Trial sponsors